JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by OSSWALD, W.
Right arrow Articles by GARRETT, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by OSSWALD, W.
Right arrow Articles by GARRETT, J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 174, Issue 2, 315-322, 1970
Copyright © 1970 by American Society for Pharmacology and Experimental Therapeutics


INFLUENCE OF PROPRANOLOL AND ICI 50,172 ON THE CARDIOVASCULAR ACTIONS OF CATECHOLAMINES AS MODIFIED BY ERGOTAMINE

W. OSSWALD 1, S. GUIMARÃES 1, and J. GARRETT 1

1 Laboratório de Farmacologia, Faculdade de Medicina, Porto, Portugal

The action of ergotamine on several responses of the anesthetized dog (blood pressure, heart rate, heart contractile force, peripheral blood flow, perfusion pressure of the hind limb and contractions of the retractor penis) to epinephrine and isoproterenol were evaluated. Whereas ergotamine neither stimulated nor blocked beta receptors, it blocked the alpha receptors of the peripheral vasculature and of the retractor penis in doses which did not cause a reduction in the pressor response to epinephrine but induced reversal of isoproterenol. The pressor responses to epinephrine and isoproterenol after ergotamine were prevented or antagonized by the beta blocking drugs propranolol and ICI 50,172. It is concluded that at least two factors are involved in the elicitation of preasor responses to epinephrine and isoproterenol after ergotamine, namely, the unaffected cardiostimulant action of the amines and the reduction in the capacity of the vascular bed caused by ergotamine.

Submitted on June 9, 1969
Accepted on April 6, 1970







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics.